These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35790049)

  • 1. Clinical effectiveness of baloxavir marboxil against influenza in three seasons.
    Kakuya F; Okubo H; Fujiyasu H; Kurisawa MJ; Kinebuchi T
    Pediatr Int; 2022 Jan; 64(1):e15169. PubMed ID: 35790049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons.
    Sun Y; Wagatsuma K; Saito R; Sato I; Kawashima T; Saito T; Shimada Y; Ono Y; Kakuya F; Minato M; Kodo N; Suzuki E; Kitano A; Chon I; Phyu WW; Li J; Watanabe H
    Antiviral Res; 2024 Aug; 228():105938. PubMed ID: 38897317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
    Wagatsuma K; Saito R; Chon I; Phyu WW; Fujio K; Kawashima T; Sato I; Saito T; Minato M; Kodo N; Suzuki E; Ono Y; Masaki H; Shirahige Y; Kitano A; Hamabata H; Yuyang S; Jiaming L; Watanabe H
    Antiviral Res; 2022 May; 201():105310. PubMed ID: 35358601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
    Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
    Chong Y; Kawai N; Tani N; Bando T; Takasaki Y; Shindo S; Ikematsu H
    Antiviral Res; 2021 Aug; 192():105092. PubMed ID: 34052230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.
    Chon I; Wagatsuma K; Saito R; Tang JW; Isamu S; Suzuki E; Shirahige Y; Kawashima T; Minato M; Kodo N; Masaki H; Hamabata H; Yoshioka S; Ichikawa Y; Sun Y; Li J; Otoguto T; Watanabe H
    Antiviral Res; 2024 Sep; 229():105956. PubMed ID: 38969237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
    Ando Y; Noshi T; Sato K; Ishibashi T; Yoshida Y; Hasegawa T; Onishi M; Kitano M; Oka R; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
    J Antimicrob Chemother; 2021 Jan; 76(1):189-198. PubMed ID: 33035324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season.
    Goto T; Kawai N; Bando T; Takasaki Y; Shindo S; Tani N; Chong Y; Ikematsu H
    Antiviral Res; 2024 Apr; 224():105853. PubMed ID: 38430970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018-2019 influenza season.
    Ikematsu H; Kawai N; Tani N; Chong Y; Iwaki N; Bando T; Tanaka O; Matsuura S; Maeda T; Doniwa K
    J Infect Chemother; 2020 Apr; 26(4):400-402. PubMed ID: 31870588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective observational study of the treatment of a nosocomial infection caused by oseltamivir-resistant influenza virus A with baloxavir marboxil.
    Fujita M; Matsumoto H; Inafuku Y; Toyama J; Fujita J
    Respir Investig; 2020 Sep; 58(5):403-408. PubMed ID: 32605828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom.
    Kommandantvold SA; Lemenuel-Diot A; Skedgel C; Pitman R; Rouse P; Zaraket H; Zhou H; Blanchet Zumofen MH
    Expert Rev Pharmacoecon Outcomes Res; 2024 Oct; 24(8):953-966. PubMed ID: 38850520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A protectin DX (PDX) analog with in vitro activity against influenza A(H1N1) viruses.
    Fortin N; Hénaut M; Goyette N; Maltais R; Sancéau JY; Marette A; Poirier D; Abed Y; Boivin G
    J Med Virol; 2024 Mar; 96(3):e29484. PubMed ID: 38402600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Variants With Reduced Baloxavir Marboxil and Oseltamivir Susceptibility in Children With Influenza A During the 2019-2020 Influenza Season.
    Sato M; Takashita E; Katayose M; Nemoto K; Sakai N; Fujisaki S; Hashimoto K; Hosoya M
    J Infect Dis; 2021 Nov; 224(10):1735-1741. PubMed ID: 33837427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
    Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
    J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients.
    Ringer M; Malinis M; McManus D; Davis M; Shah S; Trubin P; Topal JE; Azar MM
    Transpl Infect Dis; 2024 Apr; 26(2):e14249. PubMed ID: 38319665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials.
    Kuo YC; Lai CC; Wang YH; Chen CH; Wang CY
    J Microbiol Immunol Infect; 2021 Oct; 54(5):865-875. PubMed ID: 34020891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
    Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
    mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.